Infinity Pharmaceuticals Inc.

466 articles about Infinity Pharmaceuticals Inc.

• 

  Biotech Bankruptcies Skyrocket

  12/22/2023

  From Statera Biopharma and Sorrento Therapeutics to Aceragen and Infinity Pharmaceuticals, 2023 has seen a record high 28 bankruptcies in the biotech space so far. Here’s why.

• Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan

  7/25/2023

  Infinity Pharmaceuticals, Inc. announced a series of actions designed to reduce the Company’s burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc.

• Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma

  7/24/2023

  Infinity Pharmaceuticals, Inc. announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. (“MEI”).

• MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

  7/19/2023

  MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company’s special meeting on July 23, 2023.

• Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma

  7/14/2023

  Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. (“MEI”) at the special meeting of Infinity stockholders held earlier today (the “Special Meeting”).

• MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

  7/11/2023

  MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023.

• Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®)

  7/10/2023

  Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA ® ) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN).

• MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals

  7/7/2023

  MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023.

• ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.

  7/5/2023

  Infinity Pharmaceuticals, Inc. announced today that leading independent proxy advisor Institutional Shareholder Services Inc. (“ISS”) has recommended that Infinity stockholders vote FOR the merger with MEI Pharma, Inc.

• MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals

  7/5/2023

  MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that MEI Pharma shareholders vote “FOR” the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023.

• MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals

  6/29/2023

  MEI Pharma, Inc. issued the following letter to shareholders reiterating the Board of Directors recommendation to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. in connection with the Company’s special meeting on July 14, 2023.

• MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

  6/15/2023

  MEI Pharma, Inc. and Infinity Pharmaceuticals, Inc. announced that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern Time on June 19, 2023.

• Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research

  4/13/2023

  Infinity Pharmaceuticals, Inc. today announced upcoming presentations including data on eganelisib by Infinity’s collaborator, Professor Judith A. Varner of the UCSD Moores Cancer Center, La Jolla, California, at the 2023 Annual Meeting of the American Association of Cancer Research (AACR) to be held April 14 - 19, 2023 in Orlando, Florida.

• Infinity Pharmaceuticals Reports Full Year 2022 Financial Results

  3/28/2023

  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2022 financial results.

• MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

  2/23/2023

  MEI Pharma, Inc. and Infinity Pharmaceuticals, Inc. announced today that the companies entered into a definitive merger agreement for an all-stock transaction forming a company combining the expertise and resources of MEI and Infinity to advance a robust pipeline of three clinical-stage oncology drug candidates.

• Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference

  11/22/2022

  Infinity Pharmaceuticals, Inc. today announced that the Company will present and conduct 1-on-1 meetings with investors at the Piper Sandler 34th Annual Healthcare Conference taking place November 29 – December 1, 2022 in New York.

• Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/14/2022

  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its third quarter 2022 financial results, provided a business update, and in a separate press release provided more mature data from the Phase 2 MARIO-3 1L TNBC clinical trial.

• Infinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib

  11/14/2022

  Infinity Pharmaceuticals, Inc. today reported an update from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic triple negative breast cancer (TNBC) patients.

• Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast

  11/7/2022

  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022.

• Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences - Aug 31, 2022

  8/31/2022

  Infinity Pharmaceuticals, Inc. announced that the Company will present and conduct 1-on-1 meetings with investors at the 2022 Wells Fargo Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference.